Cargando…
Risk Factors of Progression in Low-tumor Burden Follicular Lymphoma Initially Managed by Watch and Wait in the Era of PET and Rituximab
Patients (pts) with asymptomatic low-burden follicular lymphoma (FL) are usually observed at diagnosis. Time to lymphoma treatment (TLT) initiation can however be very heterogeneous and risk factors of progression are poorly studied. Our study evaluated 201 pts with grade 1–3a low-tumor burden FL di...
Autores principales: | Rodier, Cyrielle, Kanagaratnam, Lukshe, Morland, David, Herbin, Adélie, Durand, Amandine, Chauchet, Adrien, Choquet, Sylvain, Colin, Philippe, Casasnovas, René Olivier, Deconinck, Eric, Godard, François, Delmer, Alain, Rossi, Cédric, Durot, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146112/ https://www.ncbi.nlm.nih.gov/pubmed/37125257 http://dx.doi.org/10.1097/HS9.0000000000000861 |
Ejemplares similares
-
Cerebellum/liver index in pretherapeutic (18)F-FDG PET/CT as a predictive marker of progression-free survival in follicular lymphoma treated by immunochemotherapy and rituximab maintenance
por: Godard, François, et al.
Publicado: (2022) -
Pretreatment CT Texture Parameters as Predictive Biomarkers of Progression-Free Survival in Follicular Lymphoma Treated with Immunochemotherapy and Rituximab Maintenance
por: Durot, Carole, et al.
Publicado: (2023) -
Baseline (18)F-FDG Metabolic Tumor Volume Predicts Response to Rituximab Induction in Post-transplant Lymphoproliferative Disorders: A Multi-institutional Retrospective Study
por: Morland, David, et al.
Publicado: (2023) -
Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era
por: Yuda, Sayako, et al.
Publicado: (2016) -
The outcome of watchful waiting in patients with previously treated follicular lymphoma
por: Fujino, Takahiro, et al.
Publicado: (2022)